Document:

EXHIBIT 10.132
                             SUBSCRIPTION AGREEMENT

                                                                  August 1, 2003

Dear Subscriber:

         You, together with other subscribers (each a "Subscriber") hereby agree
to purchase,  and Calypte Biomedical  Corporation,  a Delaware  corporation (the
"Company"),  hereby agrees to issue and to sell to the Subscriber, Shares of the
Company's   $.03  par  value  common  stock  (the  "Company   Shares")  for  the
consideration as set forth on the signature page hereof ("Purchase Price"). (The
Company  Shares  are  sometimes  referred  to  herein as the  "Shares",  "Common
Shares",  "Securities", or "Common Stock"). Upon acceptance of this Agreement by
the Subscriber,  the Company shall issue and deliver the Shares against payment,
by federal  funds wire  transfer,  or bank,  or certified  check of the Purchase
Price.

                  The  following  terms  and  conditions  shall  apply  to  this
Subscription.

                  1. SUBSCRIBER'S REPRESENTATIONS AND WARRANTIES. The Subscriber
hereby represents and warrants to and agrees with the Company that:

                           (a)  INFORMATION ON COMPANY.  The Subscriber has been
furnished  with the Company's  Form 10-K for the year ended December 31, 2002 as
filed with the Securities and Exchange  Commission (the  "Commission")  together
with all  subsequently  filed forms  10-QSB,  8-K,  Proxy  Statement,  and other
publicly  available  filings made with the Commission  (hereinafter  referred to
collectively  as the "Reports").  In addition,  the Subscriber has received from
the  Company  such  other  information  concerning  its  operations,   financial
condition and other matters as the Subscriber has requested (such information in
writing is collectively,  the "Other Written  Information"),  and considered all
factors  the  Subscriber  deems  material in  deciding  on the  advisability  of
investing in the Shares of Common Stock.

                           (b) INFORMATION ON SUBSCRIBER.  The Subscriber is and
was not a "U.S.  person",  as  defined in  Regulation  S  promulgated  under the
Securities  Act of 1933 at the time the  offer or sale of the  Shares  of Common
Stock is made.  Additionally,  Subscriber is an "accredited  investor",  as such
term is  defined  in  Regulation  D  promulgated  by the  Commission  under  the
Securities  Act of  1933,  as  amended  (the  "1933  Act"),  is  experienced  in
investments and business matters,  has made investments of a speculative  nature
and has  purchased  securities  of United  States  publicly-owned  companies  in
private placements in the past and, with its representatives, has such knowledge
and  experience in financial,  tax and other  business  matters as to enable the
Subscriber to utilize the information  made available by the Company to evaluate
the merits and risks of and to make an informed investment decision with respect
to the  proposed  purchase,  which  represents  a  speculative  investment.  The
Subscriber  has the authority and is duly and legally  qualified to purchase and
own the Shares of Common Stock.  The Subscriber is able to bear the risk of such
investment for an indefinite  period and to afford a complete loss thereof.  The
information  set forth on the signature page hereto  regarding the Subscriber is
accurate.

                           (c) PURCHASE OF SHARES AND LOCK-UP PROVISION.  On the
Closing Date, the Subscriber will purchase the Company Stock for its own account
at a price of $0.30 per share  and not with a view to any  distribution  thereof
and that the purchase of the Common Stock is intended to be made as an "Offshore
Transaction"  as  defined in  Regulation  S. The  Subscriber  agrees to hold the
Common  Stock  purchased  under the  Agreement  for a period  of  twelve  months
following the date of closing.

                                       1
<PAGE>

                           (d) COMPLIANCE  WITH  SECURITIES  ACT. The Subscriber
understands and agrees that the Shares have not been  registered  under the 1933
Act,  by  reason  of their  issuance  in a  transaction  that  does not  require
registration  under  the  1933  Act  (based  in  part  on  the  accuracy  of the
representations  and warranties of Subscriber  contained herein),  and that such
Shares  of  Common  Stock  must be  held  unless  a  subsequent  disposition  is
registered under the 1933 Act or is exempt from such registration.

                           (e) COMPANY SHARES  LEGEND.  The Company Shares shall
bear the following legend,  unless same shall have been included in an effective
registration statement under the 1933 Act:

                  "THE  SHARES  REPRESENTED  BY THIS  CERTIFICATE  HAVE NOT BEEN
                  REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THESE
                  SHARES  MAY  NOT  BE  SOLD,   OFFERED  FOR  SALE,  PLEDGED  OR
                  HYPOTHECATED  IN  THE  ABSENCE  OF AN  EFFECTIVE  REGISTRATION
                  STATEMENT  UNDER SUCH  SECURITIES ACT OR AN OPINION OF COUNSEL
                  REASONABLY SATISFACTORY TO CALYPTE BIOMEDICAL CORPORATION THAT
                  SUCH REGISTRATION IS NOT REQUIRED".

                            (f)  COMMUNICATION  OF OFFER.  The offer to sell the
Shares of Common Stock was directly  communicated to the Subscriber.  At no time
was the  Subscriber  presented  with or solicited  by any leaflet,  newspaper or
magazine  article,  radio or  television  advertisement,  or any  other  form of
general  advertising  or  solicited or invited to attend a  promotional  meeting
otherwise than in connection and concurrently with such communicated offer.

                           (g)  CORRECTNESS OF  REPRESENTATIONS.  The Subscriber
represents  that  the  foregoing  representations  and  warranties  are true and
correct as of the date hereof and, unless the Subscriber  otherwise notifies the
Company prior to the Closing Date (as  hereinafter  defined),  shall be true and
correct as of the Closing Date.  The foregoing  representations  and  warranties
shall survive the Closing Date.

                  2.  COMPANY   REPRESENTATIONS  AND  WARRANTIES.   The  Company
represents and warrants to and agrees with the Subscriber that:

                           (a) DUE  INCORPORATION.  The  Company and each of its
subsidiaries,  if any, is a corporation duly organized,  validly existing and in
good  standing  under  the  laws  of  the  respective   jurisdictions  of  their
incorporation and have the requisite corporate power to own their properties and
to carry on their business as now being  conducted.  The Company and each of its
subsidiaries is duly qualified as a foreign corporation to do business and is in
good standing in each jurisdiction where the nature of the business conducted or
property  owned by it makes  such  qualification  necessary,  other  than  those
jurisdictions  in which the  failure  to so  qualify  would not have a  material
adverse  effect  on the  business,  operations  or  financial  condition  of the
Company.

                           (b)  OUTSTANDING  STOCK.  All issued and  outstanding
shares of capital  stock of the  Company and each of its  subsidiaries  has been
duly authorized and validly issued and are fully paid and non-assessable.

                           (c)  AUTHORITY;  ENFORCEABILITY.  This  Agreement and
other  agreements  delivered  together  with  this  Agreement  or in  connection
herewith  have been duly  authorized,  executed and delivered by the Company and
are valid and binding  agreements  enforceable  in accordance  with their terms,
subject  to  bankruptcy,   insolvency,

                                       2
<PAGE>

fraudulent  transfer,  reorganization,  moratorium  and similar  laws of general
applicability  relating  to or  affecting  creditors'  rights  generally  and to
general  principles  of equity;  and the  Company has full  corporate  power and
authority necessary to enter into this Agreement,  and such other agreements and
to perform its obligations hereunder and under all other agreements entered into
by the Company relating hereto.

                           (d) ADDITIONAL ISSUANCES.  Except as set forth in the
Reports and Other Written Information as described in Section 1(a), there are no
outstanding  agreements or preemptive or similar rights  affecting the Company's
common  stock or equity  and no  outstanding  rights,  warrants  or  options  to
acquire,  or instruments  convertible into or exchangeable for, or agreements or
understandings  with  respect  to the sale or  issuance  of any shares of common
stock  or  equity  of  the  Company  or  other  equity  interest  in  any of the
subsidiaries of the Company.

                           (e) CONSENTS. No consent, approval,  authorization or
order  of  any  court,   governmental   agency  or  body  or  arbitrator  having
jurisdiction  over  the  Company,  or  any  of  its  affiliates,   the  National
Association  of  Securities  Dealers,  Inc.  ("NASD"),  NASDAQ or the  Company's
Shareholders  is  required  for  execution  of this  Agreement,  and  all  other
agreements  entered into by the Company  relating  thereto,  including,  without
limitation,  the issuance and sale of the Securities, and the performance of the
Company's obligations hereunder and under all such other agreements.

                           (f)  NO   VIOLATION   OR   CONFLICT.   Assuming   the
representations  and  warranties  of the  Subscriber in Paragraph 1 are true and
correct and the Subscriber  complies with its obligations  under this Agreement,
neither the issuance and sale of the Shares of Common Stock nor the  performance
of the  Company's  obligations  under this  Agreement  and all other  agreements
entered into by the Company relating thereto by the Company will:

                                    (i)  violate,  conflict  with,  result  in a
breach of, or  constitute a default (or an event which with the giving of notice
or the lapse of time or both would be reasonably likely to constitute a default)
under (A) the  certificate of  incorporation,  charter or bylaws of the Company,
(B) to the Company's knowledge, any decree, judgment,  order, law, treaty, rule,
regulation or determination applicable to the Company of any court, governmental
agency or body, or arbitrator having jurisdiction over the Company or any of its
affiliates  or over  the  properties  or  assets  of the  Company  or any of its
affiliates,  (C) the terms of any bond, debenture, note or any other evidence of
indebtedness,  or any agreement,  stock option or other similar plan, indenture,
lease,  mortgage,  deed of trust or other instrument to which the Company or any
of its  affiliates is a party,  by which the Company or any of its affiliates is
bound, or to which any of the properties of the Company or any of its affiliates
is  subject,  or (D) the terms of any  "lock-up"  or  similar  provision  of any
underwriting or similar agreement to which the Company, or any of its affiliates
is a party except the violation, conflict, breach, or default of which would not
have a material adverse effect on the Company; or

                                    (ii) result in the creation or imposition of
any lien,  charge or  encumbrance  upon the Shares of Common Stock or any of the
assets of the Company, its subsidiaries or any of its affiliates.

                           (g) THE  SHARES  OF COMMON  STOCK.  The  Shares  upon
issuance:

                                    (i) are,  or will be,  free and clear of any
security interests, liens, claims or other encumbrances, subject to restrictions
upon transfer under the 1933 Act and State laws;

                                    (ii) have been, or will be, duly and validly
authorized  and on the date of issuance and on the Closing Date, as  hereinafter
defined,  and will be duly and validly issued, fully paid and nonassessable (and
if  registered  pursuant to the 1933 Act,  and resold  pursuant to an  effective
Registration Statement will be free trading and unrestricted,  provided that the
Subscriber complies with the Prospectus delivery requirements);

                                       3
<PAGE>

                                    (iii)  will not have been  issued or sold in
violation of any preemptive or other similar rights of the holders of any Shares
of Common Stock of the Company; and

                                    (iv) will not subject the holders thereof to
personal liability by reason of being such holders.

                           (h) LITIGATION. Except as disclosed in the Securities
and Exchange Commission filings, Reports or Other Written Information,  there is
no pending or, to the best knowledge of the Company,  threatened  action,  suit,
proceeding or investigation  before any court,  governmental  agency or body, or
arbitrator having  jurisdiction over the Company, or any of its affiliates which
litigation if adversely  determined  could have a material adverse effect on the
Company.

                           (i) REPORTING COMPANY. The Company is a publicly-held
company  subject to reporting  obligations  pursuant to Sections 15(d) and 13 of
the Securities Exchange Act of 1934, as amended (the "1934 Act") and has a class
of common  shares  registered  pursuant  to Section  12(g) of the 1934 Act.  The
Company's  common  stock  is  listed  for  trading  on the  OTC  Bulletin  Board
("Bulletin Board").  Pursuant to the provisions of the 1934 Act, the Company has
filed all reports and other materials  required to be filed  thereunder with the
Securities and Exchange Commission during the preceding twelve months.

                           (j) NO  MARKET  MANIPULATION.  The  Company  has  not
taken,  and will not take,  directly or indirectly,  any action  designed to, or
that might  reasonably  be  expected  to,  cause or result in  stabilization  or
manipulation  of the price of the common stock of the Company to facilitate  the
sale or resale of the  Shares of Common  Stock or affect  the price at which the
Shares may be issued or resold.

                           (k)  INFORMATION   CONCERNING  COMPANY.  The  Reports
contain all material  information relating to the Company and its operations and
financial  condition as of their respective dates which  information is required
to be disclosed therein.  Since the date of the financial statements included in
the Reports,  and except as modified in the Other Written  Information or in the
Schedule  hereto,  there has been no material  adverse  change in the  Company's
business,  financial  condition or affairs not  disclosed  in the  Reports.  The
Reports do not contain any untrue  statement of a material fact or omit to state
a  material  fact  required  to be  stated  therein  or  necessary  to make  the
statements therein not misleading in light of the circumstances when made.

                           (l) DILUTION.  The Company's  executive  officers and
directors  have studied and fully  understand the nature of the Stock being sold
hereby and recognize that they have a potential  dilutive  effect.  The board of
directors of the Company has  concluded,  in its good faith  business  judgment,
that  such  issuance  is in the  best  interests  of the  Company.  The  Company
specifically  acknowledges  that its obligation to issue the Shares upon payment
is binding upon the Company and  enforceable,  except as otherwise  described in
this Subscription  Agreement,  regardless of the dilution such issuance may have
on the ownership interests of other shareholders of the Company.

                           (m)STOP  TRANSFER.  The  Shares of  Common  Stock are
restricted  securities  as of the date of this  Agreement.  The Company will not
issue any stop  transfer  order or other  order  impeding  the  sale,  resale or
delivery of the Stock, except as may be required by federal securities laws.

                                       4
<PAGE>

                           (n) DEFAULTS. To the best of the Company's knowledge,
neither  the  Company  nor  any  of  its  subsidiaries  is in  violation  of its
Certificate  of  Incorporation  or ByLaws.  Neither  the  Company nor any of its
subsidiaries  is (i) in  default  under or in  violation  of any other  material
agreement  or  instrument  to  which  it is a party or by which it or any of its
properties  are bound or  affected,  which  default  or  violation  would have a
material  adverse  effect on the  Company,  (ii) in default  with respect to any
order of any court,  arbitrator or  governmental  body or subject to or party to
any order of any court or governmental authority arising out of any action, suit
or proceeding  under any statute or other law  respecting  antitrust,  monopoly,
restraint  of trade,  unfair  competition  or similar  matters,  or (iii) to its
knowledge in violation of any statute,  rule or regulation  of any  governmental
authority which violation would have a material adverse effect on the Company.

                           (o) NO INTEGRATED OFFERING. The Company believes that
neither the Company, nor any of its affiliates,  nor any person acting on its or
their  behalf,  has  directly  or  indirectly  made any  offers  or sales of any
security or solicited any offers to buy any security  under  circumstances  that
would cause the offer of the Shares of Common Stock  pursuant to this  Agreement
to be  integrated  with prior  offerings by the Company for purposes of the 1933
Act  or any  applicable  stockholder  approval  provisions,  including,  without
limitation,  under the rules and  regulations of the Bulletin Board nor will the
Company or any of its affiliates or  subsidiaries  take any action or steps that
would  cause the  offering  of the  Common  Stock to be  integrated  with  other
offerings.  The Company has not  conducted  and will not conduct any offer other
than the transactions contemplated hereby that will be integrated with the offer
or issuance  of the Common  Stock.  Subscribers  warrant  and  represent  to the
Company  that each  Subscriber  has not  taken any  action  that  would  cause a
violation of the  integration  regulation as  promulgated by Federal Law as made
and provided.

                           (p) NO GENERAL SOLICITATION. Neither the Company, nor
any of its affiliates,  nor to its knowledge,  any person acting on its or their
behalf, has engaged in any form of general  solicitation or general  advertising
(within the meaning of Regulation S or D under the Act) in  connection  with the
offer or sale of the Common Stock.

                           (q) LISTING. The Company's Common Stock is quoted on,
and listed for trading on the Bulletin  Board.  The Company has not received any
oral or written  notice that its Common Stock will be delisted from the Bulletin
Board or that the Company's  Common Stock does not meet all requirements for the
continuation of such listing.

                           (r) NO  UNDISCLOSED  LIABILITIES.  The Company has no
liabilities or obligations which are material, individually or in the aggregate,
which are not  disclosed in the  Reports,  Securities  and  Exchange  Commission
filings,  and Other  Written  Information,  other  than  those  incurred  in the
ordinary course of the Company's  businesses  since December 31, 2002 and which,
individually  or in the  aggregate,  would not  reasonably be expected to have a
material adverse effect on the Company's financial condition.

                           (s) NO  UNDISCLOSED  EVENTS OR  CIRCUMSTANCES.  Since
December 31, 2002, no event or circumstance  has occurred or exists with respect
to the Company or its businesses, properties, operations or financial condition,
that,  under applicable law, rule or regulation,  requires public  disclosure or
announcement  prior to the date  hereof by the Company but which has not been so
publicly announced or disclosed in the Reports.

                           (t)  CAPITALIZATION.  The  authorized and outstanding
capital  stock of the Company as of the date of this  Agreement  and the Closing
Date are set forth on Schedule  2(t) hereto.  Except as set forth in the Reports
and Other Written  Information and Securities and Exchange  Commission  filings,
there are no options, warrants, or rights to subscribe to, securities, rights or
obligations  convertible  into  or  exchangeable  for or  giving  any  right  to
subscribe for any shares of capital stock of the Company. All of the outstanding
shares of Common Stock of the Company have been duly and validly  authorized and
issued and are fully paid and nonassessable.

                                       5
<PAGE>

                           (u)  CORRECTNESS  OF  REPRESENTATIONS.   The  Company
represents  that  the  foregoing  representations  and  warranties  are true and
correct as of the date hereof in all material respects,  and, unless the Company
otherwise  notifies the Subscriber  prior to the Closing Date, shall be true and
correct  in  all  material  respects  as of  the  Closing  Date.  The  foregoing
representations and warranties shall survive the Closing Date.

                  3. REGULATION S OFFERING. This Offering is being made pursuant
to the exemption from the registration provisions of the Securities Act of 1933,
as amended,  afforded by  Regulation S promulgated  there under.  On the Closing
Date, the Company will provide an opinion from the Company's legal counsel based
upon the  representation  of  Subscribers  opining  on the  availability  of the
Regulation  S exemption as it relates to the offer and issuance of the Shares of
Common Stock.

                  4. REISSUANCE OF SHARES OF COMMON STOCK. The Company agrees to
reissue certificates  representing the Shares of Common Stock without the legend
set forth in  Sections  1(e)  above at such time as (a) the  holder  thereof  is
permitted to and disposes of such Shares of Common Stock pursuant to Rule 144(d)
and/or  Rule  144(k)  under the 1933 Act or  Regulation  "S" in the  opinion  of
counsel reasonably satisfactory to the Company, or (b) upon resale subject to an
effective  registration statement after the Shares are registered under the 1933
Act. The Company agrees to cooperate with the Subscriber in connection  with all
resales  pursuant  to Rule 144(d) and Rule  144(k) and  provide  legal  opinions
necessary  to allow such resales  provided  the Company and its counsel  receive
requested  written  representations  from the Subscriber and selling broker,  if
any. Provided the Subscriber provides required certifications and representation
letters,  if any, if the Company  fails to remove any legend as required by this
Section 4 (a "Legend Removal  Failure"),  then beginning on the tenth (10th) day
following the date that the  Subscriber  has requested the removal of the legend
and  delivered all items  reasonably  required by the Company to be delivered by
the Subscriber, the Company continues to fail to remove such legend, the Company
shall pay to each  Subscriber or assignee  holding  Shares,  subject to a Legend
Removal Failure,  as liquidated damages and not a penalty an amount equal to one
percent (1%) of the  Purchase  Price of the Shares  subject to a Legend  Removal
Failure  per day that such  failure  continues.  If during any twelve (12) month
period, the Company fails to remove any legend as required by this Section 4 for
an aggregate of thirty (30) days,  each  Subscriber or assignee  holding  Shares
subject to a Legend Removal  Failure may, at its option,  require the Company to
purchase all or any portion of the Shares  subject to a Legend  Removal  Failure
held by such  Subscriber  or  assignee at a price per share equal to 120% of the
applicable Purchase Price.

                  5.  REGULATION  D. In the  event  that a  Subscriber  does not
qualify  under  Regulation  S and  qualifies  under  Regulation  D, the  Company
covenants and agrees that if the Company fails to file a Registration  Statement
for Company  Shares  within  ninety (90) days from the Closing Date  pursuant to
Section 10.1(iv) below, then for so long as such  registration  statement is not
effective and as any of the Company Shares remain outstanding and continue to be
"restricted  Shares" within the meaning of Rule 144, the Company shall, in order
to permit  resales of any of the Company  Shares  pursuant to Rule 144 under the
1933 Act,  (a) continue to file all  material  required to be filed  pursuant to
Section 13(a) or 15(d) of the 1934 Act.

                 6.  INDEMNIFICATION.  The  Company  on the  one  hand,  and the
Subscriber on the other hand,  agree to indemnify the other against and hold the
other  harmless  from any and all  liabilities  to any  other  persons  claiming
brokerage  commissions  or finder's fees other than Careen Limited on account of
services  purported to have been rendered on behalf of the indemnifying party in
connection  with this  Agreement  or the  transactions  contemplated  hereby and
arising out of such party's actions. The Company and the Subscriber represent to
each  other  that  there  are  no  other  parties   entitled  to  receive  fees,
commissions,  or similar  payments in connection with the offering  described in
the Subscription Agreement.

                                       6
<PAGE>

                  7. COVENANTS OF THE COMPANY.  The Company covenants and agrees
with the Subscriber as follows:

                           (a) The Company will advise the Subscriber,  promptly
after it receives notice of issuance by the Securities and Exchange  Commission,
any state securities  commission or any other  regulatory  authority of any stop
order or of any order preventing or suspending any offering of any securities of
the Company,  or of the suspension of the  qualification  of the Common Stock of
the Company for offering or sale in any  jurisdiction,  or the initiation of any
proceeding for any such purpose.

                           (b) The  Company  will  maintain  the  listing of its
Common Stock on the NASDAQ SmallCap Market,  NASDAQ National Market System, NASD
OTC  Bulletin  Board,  or New  York  Exchange,  or  Pink  Sheet  Trading  Market
(whichever  of the foregoing is at the time the  principal  trading  exchange or
market for the  Common  Stock (the  "Principal  Market"),  and will use its best
efforts to comply,  in all respects,  with the Company's  reporting,  filing and
other  obligations  under the  bylaws or rules of the  National  Association  of
Securities Dealers ("NASD") and such exchanges, as applicable.  The Company will
provide the Subscriber  copies of all notices it receives  notifying the Company
of the  threatened  and actual  delisting of the Common Stock from any Principal
Market.

                           (c) The Company  shall notify the  Commission,  NASD,
the Principal Market and applicable state authorities,  in accordance with their
requirements,  if any, of the transactions  contemplated by this Agreement,  and
shall take all other  necessary  action and  proceedings  as may be required and
permitted  by  applicable  law,  rule and  regulation,  for the  legal and valid
issuance of the Shares of Common Stock to the  Subscriber  and promptly  provide
copies thereof to Subscriber.

                           (d) From the Closing  Date and until at least one (1)
year after the  effectiveness of the Registration  Statement on Form S-2 or such
other Registration  Statement  described in Section 10.1(iv) hereof, the Company
will (i) cause its Common  Stock to continue  to be  registered  under  Sections
12(b) or  12(g) of the  Exchange  Act,  (ii)  comply  in all  respects  with its
reporting and filing  obligations  under the Exchange Act, (iii) comply with all
reporting  requirements  that are applicable to an issuer with a class of Shares
registered  pursuant to Section  12(g) of the Exchange Act, and (iv) comply with
all requirements  related to any  registration  statement filed pursuant to this
Agreement.  The Company will use its best efforts not to take any action or file
any  document  (whether or not  permitted  by the Act or the Exchange Act or the
rules  thereunder) to terminate or suspend such  registration or to terminate or
suspend its reporting and filing  obligations under said Acts until one (1) year
after the actual  effective  date of the  Registration  Statement on Form S-2 or
other  Registration  Statement  described in Section 10.1(iv) hereof.  Until the
resale of the Company  Shares by the  Subscriber,  the Company will use its best
efforts to continue the listing of the Common  Stock on the  Bulletin  Board and
will  comply in all  respects  with the  Company's  reporting,  filing and other
obligations under the bylaws or rules of Bulletin Board.

                  8.   COVENANTS  OF  THE  COMPANY  AND   SUBSCRIBER   REGARDING
INDEMNIFICATION.

                           (a) The Company  agrees to indemnify,  hold harmless,
reimburse  and defend  Subscriber,  Subscriber's  officers,  directors,  agents,
affiliates,  control  persons,  and principal  shareholders,  against any claim,
cost, expense, liability, obligation, loss or damage (including reasonable legal
fees) of any nature,  incurred by or imposed upon  Subscriber or any such person
which results, arises out of or is based upon (i) any material misrepresentation
by Company or breach of any  warranty  by  Company in this  Agreement  or in any
Exhibits or Schedules  attached hereto,  or other agreement  delivered  pursuant

                                       7
<PAGE>

hereto; or (ii) after any applicable  notice and/or cure periods,  any breach or
default in  performance  by the  Company of any  covenant or  undertaking  to be
performed by the Company  hereunder,  or any other agreement entered into by the
Company and Subscribers relating hereto.

                           (b)  Subscriber  agrees to indemnify,  hold harmless,
reimburse and defend the Company and each of the Company's officers,  directors,
agents, affiliates, control persons against any claim, cost, expense, liability,
obligation,  loss or damage  (including  reasonable  legal  fees) of any nature,
incurred by or imposed upon the Company or any such person which results, arises
out of or is based upon (i) any material misrepresentation by Subscriber in this
Agreement or in any Exhibits or Schedules  attached  hereto,  or other agreement
delivered  pursuant  hereto;  or (ii) after any  applicable  notice  and/or cure
periods,  any breach or default in  performance by Subscriber of any covenant or
undertaking  to be performed by  Subscriber  hereunder,  or any other  agreement
entered into by the Company and Subscribers relating hereto.

                           (c) The  procedures  set forth  herein shall apply to
the indemnifications set forth in Sections 8(a) and 8(b) above.

                  10.1.  REGISTRATION  RIGHTS.  The  Company  hereby  grants the
following registration rights to holders of the Shares of Common Stock.

                           (a) The Company hereby agrees use its best commercial
efforts to register the Shares of Common Stock herein on a Form S-2 or any other
applicable Form with the Securities and Exchange  Commission.  Subscribers agree
that the registration will be on an optional  piggy-back or single  registration
basis at the option of the Company, and that the Company will bear all costs and
expenses of the registration.

                           (b) The Company  agrees to give ten (10) days written
notice to all  Subscribers  of the  filing of the  Registration  Statement,  and
Subscribers  agree that each will  cooperate  with the Company in providing  the
necessary  information  required  by  each  Subscriber  to  file a  Registration
Statement on that Subscriber's behalf.

                           (c) Each  Subscriber  agrees to  execute  the  within
Agreement and to subscribe for the number of Shares of Common Stock as agreed to
by Subscriber.

                  10.2. REGISTRATION PROCEDURES.  If and whenever the Company is
required by the provisions  hereof to effect the  registration  of any Shares of
Common Stock under the Act, the Company will, as expeditiously as possible:

                           (a)   prepare   and  file  with  the   Commission   a
Registration  Statement  with respect to such Shares of Common Stock and use its
best efforts to cause such Registration Statement to become and remain effective
for the period of the distribution  contemplated  thereby  (determined as herein
provided),  and  promptly  provide  to the  holders  of Shares  of Common  Stock
("Sellers") copies of all filings with the Commission;

                           (b)  prepare  and  file  with  the  Commission   such
amendments  and  supplements to such  Registration  Statement and the prospectus
used in  connection  therewith  as may be  necessary  to keep such  Registration
Statement  effective  until the latest of: (i) 180 days  following the effective
date of the Registration Statement;

                                       8
<PAGE>

                           (c) furnish to the  Seller,  such number of copies of
the Registration  Statement and the prospectus  included therein (including each
preliminary  prospectus)  as such  Seller  reasonably  may  request  in order to
facilitate the public sale or their  disposition  of the  securities  covered by
such Registration Statement;

                           (d) use its best  efforts to  register or qualify the
Seller's Shares of Common Stock covered by such Registration Statement under the
securities  or  "blue  sky"  laws  of such  jurisdictions  as the  Seller  shall
reasonably designate, provided, however, that the Company shall not for any such
purpose be  required  to qualify  generally  to  transact  business as a foreign
corporation  in any  jurisdiction  where it is not so qualified or to consent to
general service of process in any such jurisdiction;

                           (e) list the Shares of Common  Stock  covered by such
Registration Statement with any securities exchange on which the Common Stock of
the Company is then listed;

                           (f)  immediately  notify the Seller when a prospectus
relating  thereto is required to be delivered under the Act, of the happening of
any event of which the Company has knowledge as a result of which the prospectus
contained in such Registration  Statement, as then in effect, includes an untrue
statement of a material  fact or omits to state a material  fact  required to be
stated  therein or necessary to make the  statements  therein not  misleading in
light of the circumstances then existing;

                           (g) make available for inspection by the Seller,  and
any attorney retained by the Seller,  all publicly  available,  non-confidential
financial and other records, pertinent corporate documents and properties of the
Company, and cause the Company's officers, directors and employees to supply all
publicly available,  non-confidential  information  reasonably  requested by the
attorney for Seller in connection with such Registration Statement;

                           (h) will notify the  Subscriber of the  effectiveness
of the Registration Statement within one business day of such event.

                  10.3.   PROVISION  OF  DOCUMENTS.   In  connection  with  each
registration  hereunder,  the Seller will furnish to the Company in writing such
information and  representation  letters with respect to itself and the proposed
distribution  by  it as  reasonably  shall  be  necessary  in  order  to  assure
compliance with federal and applicable state securities laws. In connection with
each   registration   pursuant  to  Section  10.1(i)  or  10.1(ii)  covering  an
underwritten  public offering,  the Company and the Seller agree to enter into a
written agreement with the managing underwriter in such form and containing such
provisions as are customary in the  securities  business for such an arrangement
between such  underwriter  and  companies of the Company's  size and  investment
stature.

                  10.4.  EXPENSES.  All  expenses  incurred  by the  Company  in
complying with Section 10, including,  without limitation,  all registration and
filing  fees,   printing  expenses,   fees  and  disbursements  of  counsel  and
independent  public  accountants for the Company,  fees and expenses  (including
reasonable  counsel  fees)  incurred in  connection  with  complying  with state
securities or "blue sky" laws,  fees of the National  Association  of Securities
Dealers, Inc., transfer taxes, fees of transfer agents and registrars, and costs
of insurance are called "Registration  Expenses". All underwriting discounts and
selling commissions  applicable to the sale of Shares of Common Stock, including
any fees and  disbursements  of any special  counsel to the  Seller,  are called
"Selling Expenses". The Seller shall pay the fees of its own additional counsel,
if any. The Company will pay all  Registration  Expenses in connection  with the
registration statement under Section 10. All Selling Expenses in connection with
each  registration  statement  under Section 10 shall be borne by the Seller and
may be apportioned  among the Sellers in proportion to the number of shares sold
by the  Seller  relative  to the number of shares  sold under such  registration
statement or as all Sellers thereunder may agree.

                                       9
<PAGE>

                  10.5. INDEMNIFICATION AND CONTRIBUTION.

                           (a) In the event of a  registration  of any Shares of
Common Stock under the Act  pursuant to Section 10, the Company  will  indemnify
and hold harmless the Seller,  each officer of the Seller,  each director of the
Seller,  each  underwriter  of such Shares of Common Stock  thereunder  and each
other person, if any, who controls such Seller or underwriter within the meaning
of the 1933 Act, against any losses,  claims,  damages or liabilities,  joint or
several,  to which the Seller,  or such  underwriter or  controlling  person may
become  subject  under the Act or  otherwise,  insofar as such  losses,  claims,
damages or liabilities (or actions in respect thereof) arise out of or are based
upon any untrue  statement or alleged  untrue  statement  of any  material  fact
contained in any Registration  Statement under which such Shares of Common Stock
were registered under the Act pursuant to Section 10, any preliminary prospectus
or final prospectus  contained therein,  or any amendment or supplement thereof,
or arise out of or are based  upon the  omission  or alleged  omission  to state
therein a material fact  required to be stated  therein or necessary to make the
statements  therein not misleading in light of the circumstances  when made, and
will  reimburse  the Seller,  each such  underwriter  and each such  controlling
person for any legal or other expenses reasonably incurred by them in connection
with  investigating  or defending  any such loss,  claim,  damage,  liability or
action; provided, however, that the Company shall not be liable to the Seller to
the  extent  that any such  damages  arise  out of or are  based  upon an untrue
statement  or  omission  made in any  preliminary  prospectus  if (i) the Seller
failed  to send or  deliver  a copy of the  final  prospectus  delivered  by the
Company to the Seller with or prior to the delivery of written  confirmation  of
the sale by the Seller to the person asserting the claim from which such damages
arise,  (ii) the final  prospectus would have corrected such untrue statement or
alleged untrue statement or such omission or alleged  omission,  or (iii) to the
extent that any such loss, claim,  damage or liability arises out of or is based
upon an untrue  statement  or alleged  untrue  statement  or omission or alleged
omission so made in conformity with information furnished by any such Seller, or
any such controlling person in writing specifically for use in such Registration
Statement or prospectus.

                           (b)  In the  event  of a  registration  of any of the
Shares of Common  Stock  under the Act  pursuant  to Section 10, the Seller will
indemnify and hold harmless the Company,  and each person,  if any, who controls
the Company within the meaning of the Act, each officer of the Company who signs
the Registration  Statement,  each director of the Company, each underwriter and
each person who controls any underwriter  within the meaning of the Act, against
all losses,  claims,  damages or  liabilities,  joint or  several,  to which the
Company or such officer, director,  underwriter or controlling person may become
subject under the Act or otherwise,  insofar as such losses,  claims, damages or
liabilities  (or actions in respect  thereof) arise out of or are based upon any
untrue  statement or alleged untrue  statement of any material fact contained in
the  Registration  Statement  under  which  such  Shares  of Common  Stock  were
registered  under the Act pursuant to Section 10, any preliminary  prospectus or
final prospectus  contained therein,  or any amendment or supplement thereof, or
arise out of or are based upon the omission or alleged omission to state therein
a  material  fact  required  to be  stated  therein  or  necessary  to make  the
statements therein not misleading,  and will reimburse the Company and each such
officer,  director,  underwriter and  controlling  person for any legal or other
expenses  reasonably  incurred  by  them in  connection  with  investigating  or
defending any such loss, claim, damage, liability or action, provided,  however,
that the  Seller  will be liable  hereunder  in any such case if and only to the
extent that any such loss, claim,  damage or liability arises out of or is based
upon an untrue  statement  or alleged  untrue  statement  or omission or alleged
omission made in reliance upon and in conformity with information  pertaining to
such  Seller,  as such,  furnished  in  writing to the  Company  by such  Seller
specifically for use in such registration statement or prospectus, and provided,
further, however, that the liability of the Seller hereunder shall be limited to
the gross proceeds  received by the Seller from the sale of Common Stock covered
by such Registration Statement.

                                       10
<PAGE>

                           (c) Promptly  after receipt by an  indemnified  party
hereunder of notice of the commencement of any action,  such  indemnified  party
shall,  if a claim in respect  thereof is to be made  against  the  indemnifying
party  hereunder,  notify the  indemnifying  party in writing  thereof,  but the
omission  so to notify  the  indemnifying  party  shall not  relieve it from any
liability  which it may have to such  indemnified  party  other  than under this
Section  10.5(c) and shall only relieve it from any liability  which it may have
to such indemnified party under this Section 10.5(c),  except and only if and to
the extent the  indemnifying  party is prejudiced by such omission.  In case any
such action shall be brought against any  indemnified  party and it shall notify
the indemnifying party of the commencement thereof, the indemnifying party shall
be entitled to  participate  in and, to the extent it shall wish,  to assume and
undertake  the defense  thereof with counsel  satisfactory  to such  indemnified
party,  and, after notice from the indemnifying  party to such indemnified party
of its election so to assume and undertake the defense thereof, the indemnifying
party shall not be liable to such  indemnified  party under this Section 10.5(c)
for any  legal  expenses  subsequently  incurred  by such  indemnified  party in
connection with the defense thereof other than reasonable costs of investigation
and of liaison  with  counsel  so  selected,  provided,  however,  that,  if the
defendants  in any such  action  include  both  the  indemnified  party  and the
indemnifying  party and the indemnified  party shall have  reasonably  concluded
that there may be reasonable  defenses  available to it which are different from
or additional to those available to the  indemnifying  party or if the interests
of the indemnified party reasonably may be deemed to conflict with the interests
of the  indemnifying  party,  the  indemnified  parties  shall have the right to
select one separate  counsel and to assume such legal  defenses and otherwise to
participate in the defense of such action, with the reasonable expenses and fees
of such separate counsel and other expenses related to such  participation to be
reimbursed by the indemnifying party as incurred.

                           (d) In  order  to  provide  for  just  and  equitable
contribution  in the event of joint liability under the Act in any case in which
either (i) the Seller,  or any controlling  person of the Seller,  makes a claim
for  indemnification  pursuant  to  this  Section  10.5,  but  it is  judicially
determined  (by the entry of a final  judgment or decree by a court of competent
jurisdiction  and the  expiration  of time to appeal  or the  denial of the last
right of appeal)  that such  indemnification  may not be  enforced  in such case
notwithstanding  the fact that this Section 10.5 provides for indemnification in
such case, or (ii) contribution under the Act may be required on the part of the
Seller  or  controlling   person  of  the  Seller  in  circumstances  for  which
indemnification  is provided  under this Section  10.5;  then,  and in each such
case,  the Company  and the Seller  will  contribute  to the  aggregate  losses,
claims,  damages or liabilities to which they may be subject (after contribution
from others) in such  proportion so that the Seller is responsible  only for the
portion  represented  by the  percentage  that the public  offering price of its
Shares of Common Stock offered by the Registration Statement bears to the public
offering  price of all  Shares  of Common  Stock  offered  by such  Registration
Statement.

                  11.      MISCELLANEOUS.

                           (a)   NOTICES.   All  notices,   demands,   requests,
consents,  approvals,  and other communications  required or permitted hereunder
shall  be in  writing  and,  unless  otherwise  specified  herein,  shall be (i)
personally served, (ii) deposited in the mail,  registered or certified,  return
receipt  requested,  postage  prepaid,  (iii) delivered by reputable air courier
service with charges prepaid, or (iv) transmitted by hand delivery, telegram, or
facsimile,  addressed as set forth below or to such other  address as such party
shall  have  specified  most  recently  by written  notice.  Any notice or other
communication  required  or  permitted  to be given  hereunder  shall be  deemed
effective  (a) upon hand  delivery  or  delivery  by  facsimile,  with  accurate
confirmation  generated by the transmitting facsimile machine, at the address or
number  designated  below (if delivered on a business day during normal business
hours where such notice is to be received),  or the first business day following
such delivery (if delivered  other than on a business day during normal business
hours where such notice is to be  received)  or (b) on the second  business  day
following  the date of  mailing  by  express  courier  service,  fully  prepaid,
addressed to such address,  or upon actual  receipt of such  mailing,  whichever
shall first occur. The addresses for such communications shall be: (i) if to the
Company to Calypte  Biomedical  Corporation,  1265 Harbor Bay Parkway,  Alameda,
California  94502,  telecopier  number:  (510)  814-8494,  and  (ii)  if to  the
Subscriber,  to the  name,  address  and  telecopier  number  set  forth  on the
signature page hereto.

                                       11
<PAGE>

                           (b) CLOSING.  The  consummation  of the  transactions
contemplated herein shall take place at the offices of Baratta & Goldstein,  597
Fifth Avenue New York,  NY, upon the  satisfaction  of all conditions to Closing
set forth in this Agreement.  The closing date shall be the date that Subscriber
funds representing the net amount due the Company from the Purchase Price of the
Offering is  transmitted  by wire  transfer  or  otherwise  to the Company  (the
"Closing Date").

                           (c)  ENTIRE  AGREEMENT;  ASSIGNMENT.  This  Agreement
represents the entire  agreement  between the parties hereto with respect to the
subject  matter  hereof and may be amended  only by a writing  executed  by both
parties.  No right or obligation of either party shall be assigned by that party
without prior notice to and the written consent of the other party.

                           (d)  EXECUTION.  This  Agreement  may be  executed by
facsimile  transmission,  and in  counterparts,  each of which will be deemed an
original.

                           (e) LAW  GOVERNING  THIS  AGREEMENT.  This  Agreement
shall be governed by and construed in  accordance  with the laws of the State of
California without regard to principles of conflicts of laws. Any action brought
by either party against the other  concerning the  transactions  contemplated by
this  Agreement  shall be brought only in the state courts of  Caliifornia or in
the federal  courts  located in the state of  California.  Both  parties and the
individuals  executing  this  Agreement  and other  agreements  on behalf of the
Company  agree to submit to the  jurisdiction  of such courts and waive trial by
jury. The prevailing party shall be entitled to recover from the other party its
reasonable  attorney's  fees and costs.  In the event that any provision of this
Agreement or any other agreement  delivered in connection herewith is invalid or
unenforceable  under any applicable  statute or rule of law, then such provision
shall be deemed  inoperative  to the extent that it may conflict  therewith  and
shall be deemed  modified to conform  with such statute or rule of law. Any such
provision  which  may prove  invalid  or  unenforceable  under any law shall not
affect the validity or enforceability of any other provision of any agreement.

                           (f) SPECIFIC  ENFORCEMENT,  CONSENT TO  JURISDICTION.
The Company and Subscriber  acknowledge and agree that irreparable  damage would
occur  in the  event  that  any of the  provisions  of this  Agreement  were not
performed in accordance with their specific terms or were otherwise breached. It
is  accordingly  agreed that the parties  shall be entitled to an  injunction or
injunctions  to prevent or cure breaches of the provisions of this Agreement and
to enforce  specifically the terms and provisions hereof or thereof,  this being
in addition  to any other  remedy to which any of them may be entitled by law or
equity.  Subject to Section  11(e)  hereof,  each of the Company and  Subscriber
hereby waives,  and agrees not to assert in any such suit, action or proceeding,
any claim that it is not personally  subject to the  jurisdiction of such court,
that the suit, action or proceeding is brought in an inconvenient  forum or that
the venue of the suit, action or proceeding is improper. Nothing in this Section
shall affect or limit any right to serve  process in any other manner  permitted
by law.

                           (g) CONFIDENTIALITY.  The Company agrees that it will
not  disclose  publicly  or  privately  the  identity of the  Subscriber  unless
expressly  agreed to in writing by the Subscriber or only to the extent required
by law.

                           (h)  AUTOMATIC  TERMINATION.   This  Agreement  shall
automatically terminate without any further action of either party hereto if the
Closing shall not have  occurred by the tenth (10th)  business day following the
date this Agreement is accepted by the Subscriber.

         Please  acknowledge  your  acceptance  of  the  foregoing  Subscription
Agreement by signing and returning a copy to the undersigned  whereupon it shall
become a binding agreement between us.

                                       12
<PAGE>

Dated:   July    , 2003

                                       CALYPTE BIOMEDICAL CORPORATION
                                       a Delaware Corporation

                                 By:   RICHARD D. BROUNSTEIN
                                       ---------------------------------------
                                       Name:  RICHARD D. BROUNSTEIN
                                       Title: Executive Vice President and CFO

AGREED TO:

/s/ MARAT SAFIN
--------------------
MARR TECHNOLOGIES BV
SUBSCRIBER

         The  undersigned,  a Subscriber to the within  Subscription  Agreement,
agrees  to  purchase  8,333,333  Shares of Common  Stock of  Calypte  Biomedical
Corporation in accordance with the terms of the within Subscription Agreement at
$0.30 per share for the sum of $2,500,000.

                                         /s/ MARAT SAFIN
                                       --------------------------
                                       MARR TECHNOLOGIES BV
                                       SUBSCRIBER

AGREED TO:

CALYPTE BIOMEDICAL CORPORATION

By:  RICHARD D. BROUNSTEIN
-----------------------------
     Executive Vice President

                                       13<PAGE>

                                                 Portions   of   this   document
                                                 indicated  by an ++  have  been
                                                 omitted  and  filed  separately
                                                 with   the    Securities    and
                                                 Exchange Commission pursuant to
                                                 a  request   for   confidential
                                                 treatment of such information.

                                  EXHIBIT 10.1

                           EXCLUSIVE LICENSE AGREEMENT

This Exclusive License Agreement, dated April 22, 2003, ("Agreement") is entered
into by and between Scanis, Inc., a corporation organized and existing under the
laws of the State of  California,  having its  principal  place of business  and
chief  executive  office at 1111 Triton Drive,  Suite 201, Foster City, CA 94404
(hereinafter  referred to as "SCANIS") and iCAD,  Inc., a corporation  organized
and existing under the laws of the State of Delaware, having its principal place
of business and chief executive office at 4 Townsend West, Suite 17, Nashua,  NH
03063 (hereinafter referred to as "ICAD").

                                    STATEMENT

SCANIS is the owner of all right,  title and interest in and to U.S.  Patent No.
5,212,637 issued on May 18, 1993,  entitled "Method Of Investigating  Mammograms
For Masses And  Calcifications,  And Apparatus For Practicing  Such Method".  By
License Agreement dated February 18, 2003 ("Non-Exclusive License"),  SCANIS has
granted certain  non-exclusive rights to the Licensed Patent to ICAD. SCANIS now
desires to grant and ICAD  desires to receive an  exclusive  license  under such
patent  and any  related  patents  to  manufacture,  market,  and sell  products
incorporating the invention claimed in such patent and any related patents.

Now,  therefore,  in consideration of the mutual promises herein contained,  the
parties agree as follows:

     1.   DEFINITIONS. As used in this Agreement, the following terms shall have
          the meaning indicated below:

          a.   "Licensed  Patent" shall mean U.S. Patent No. 5,212,637 issued on
               May 18, 1993,  entitled "Method Of  Investigating  Mammograms For
               Masses And  Calcifications,  And  Apparatus For  Practicing  Such
               Method",   along   with   any   and   all   parents,   divisions,
               continuations,      continuations-in-part,      reissues,     and
               reexaminations of that patent.

          b.   "Licensed  Patent Rights" shall mean the rights which are held or
               which come to be held by SCANIS and its successors and assigns by
               virtue of its ownership of the Licensed Patent.

          c.   "Licensed Products" shall include equipment,  software,  firmware
               and methods for medical  imaging and/or  analysis,  whether those
               products  presently  exist or are  developed in the future,  that
               contain,  reduce to practice or otherwise incorporate some or all
               inventions  that  are  subject  to  the  Licensed  Patent  or the
               Licensed Patent Rights.

          d.   "Effective  Date"  shall mean the date on which the last party to
               this Agreement executes this Agreement.

     2.   WARRANTIES.

          a.   SCANIS warrants and represents as follows:

               i.   that it is the sole and exclusive owner of the entire right,
                    title,  and interest in and to the  Licensed  Patent and the
                    Licensed  Patent Rights and to the  invention  disclosed and
                    claimed therein;

               ii.  that it has the right to enter into this  Exclusive  License
                    Agreement with ICAD;

               iii. that   there   are   no   liens,   conveyances,   mortgages,
                    assignments,  encumbrances  or other interests or agreements
                    which would prevent or impair the full and complete exercise
                    by ICAD  (including  its  sub-licensees)  of all  rights and
                    licenses granted by SCANIS in this Agreement;

<PAGE>

               iv.  that it has not entered into,  and shall not enter into, any
                    agreements or licenses which would interfere with the rights
                    and  licenses  granted  pursuant to this  Exclusive  License
                    Agreement for the full term of this Agreement;

               v.   that as of the Effective Date of this License Agreement,  it
                    does  not  own  or  control  any  other   patent  or  patent
                    application  relating  to  software  or methods  for medical
                    imaging, except as otherwise disclosed to ICAD.

               vi.  that as of the Effective Date of this License Agreement,  it
                    has not received an assertion  from any third party,  nor an
                    opinion  from its counsel,  that the Licensed  Patent or the
                    Licensed Patent Rights are invalid or unenforceable  for any
                    reason.

               vii. that  its  entry  into  this  License   Agreement   and  the
                    performance of its obligations under this Agreement will not
                    constitute a breach of or default of any  agreement to which
                    it is bound or a  violation  of any court or  administrative
                    order or  decree to which it is  subject,  nor  require  any
                    consent,  application, or grant of authority from any person
                    or entity; and

               viii. that it knows of no claim,  proceeding, or litigation  that
                    could materially and adversely affect its ability to execute
                    or perform its obligations under this Agreement.

               ix.  that the Board of  Directors  of Scanis,  Inc.  has approved
                    this License Agreement.

          b.   ICAD warrants and represents as follows:

               i.   that it has the  right to enter  into  this  Agreement  with
                    SCANIS;

               ii.  that ICAD's entry into this Agreement and the performance of
                    ICAD's  obligations under this Agreement will not constitute
                    a breach of or default of any agreement to which it is bound
                    or a  violation  of any  court  or  administrative  order or
                    decree to which it is subject ;

     3. LICENSE, RELEASE AND COVENANT.

          a.   SCANIS, on behalf of itself and its successors and assigns in the
               Licensed Patent and Licensed Patent Rights, hereby grants to ICAD
               an   exclusive    world-wide,    irrevocable,    assignable   and
               sublicensable  license to and with respect to the Licensed Patent
               and the  Licensed  Patent  Rights,  and to  Manufacture/Sale  the
               Licensed Products.

          b.   SCANIS  further  grants to ICAD the right at its expense to cause
               SCANIS to file for  reexamination  or  re-issue  of the  Licensed
               Patent,  to permit ICAD to file for  reexamination or re-issue of
               the  Licensed  Patent in  SCANIS'  name,  as well as the right to
               defend/prosecute  any  reexamination  or re-issue of the Licensed
               Patent in SCANIS' name.  SCANIS shall  Cooperate with ICAD in any
               of these events.

          c.   ICAD agrees for itself and its  successors  and  assigns  that it
               will  not at any  time or in any  capacity  assert  any  claim or
               commence or prosecute any action,  suit,  or  proceeding  against
               SCANIS or against any direct or  indirect,  immediate  or remote,
               end user, distributor,  customer,  dealer, or supplier of SCANIS,
               for  infringement  of the  Licensed  Patent  Rights by the direct
               and/or contributory  infringement or by inducement arising out of
               the  manufacture,  use,  sale,  offer  for sale,  lease,  import,
               export,  or other  disposition  ("Manufacture/Sale")  of Licensed
               Products made, used, sold,  offered for sale,  leased,  imported,
               exported,  or  otherwise  disposed  of by or on behalf of SCANIS.
               (the  "Non-Assertion  Agreement").  The  Non-Assertion  Agreement
               shall be applicable only to Computer Aided Detection  Systems (as
               that term is generally understood in the industry)  incorporating
               Scans'   proprietary    computer   aided   detection    software,
               manufactured  and sold by Scans, its  subsidiaries,  distributors
               and resellers.

          d.   In the event of the acquisition of  substantially  all of SCANIS'
               assets or  business  by any third  party,  SCANIS  may assign its
               entire  right,  title,  and interest  (expressly  subject to this
               Agreement and the  Non-Exclusive  License) in the Licensed Patent
               and  the  Licensed  Patent  Rights  to  such  purchaser  and  the
               Non-Assertion  Agreement  shall be  thereafter  be  applicable to
               manufacture  and sales with respect to the  purchaser but only to
               the extent of the  number of units of  Computer  Aided  Detection
               Systems  sold by  SCANIS  at the time of such  acquisition,  plus
               annual  increases  thereafter equal to the greater of (1) SCANIS'
               growth  rate in the number of units of Computer  Aided  Detection
               Systems sold by SCANIS

<PAGE>

               during the twelve (12) months prior to the acquisition in the US,
               and (2)  the  rate in the  number  of  units  of  Computer  Aided
               Detection  Systems sold by the overall  market  during the twelve
               (12)   months   prior   to  the   acquisition.   Otherwise,   the
               Non-Assertion  Agreement  shall not be assignable,  acquirable or
               assumable.

          e.   SCANIS shall have no right to license or sub-license the Licensed
               Patent or the Licensed Patent Rights.

     4.   CONSIDERATION.  In  consideration  of the license  granted  under this
          Agreement,   SCANIS  shall  be  entitled  to  receive  the   following
          consideration:

          a.   An  initial  License  Fee of ++,  paid to  SCANIS  by  ICAD  upon
               execution of this Exclusive License Agreement,  and refundable by
               SCANIS to ICAD within thirty (30) days after cancellation of this
               Exclusive License Agreement as set forth herein at section 5(b).

          b.   An additional and final license fee of ++ payable upon completion
               of those conditions set forth at section 5(a), ++ within five (5)
               days  after  satisfaction  of such  conditions  and  the  balance
               payable within thirty (30) days thereafter.

          c.   ICAD agrees to pays to SCANIS an additional royalty equal to ++.

     5.   CONDITIONS PRECEDENT TO COMPLETION; CANCELATION

          a.   ICAD's  obligation  to make payments as set forth at section 4(b)
               are contingent on satisfaction  of the following  within fourteen
               (14) days after the Effective Date,  which such conditions may be
               waived by ICAD:

               i.   Patent  Office and UCC checks  confirming  that no  security
                    interests exist with respect to the Licensed Patent;

               ii.  Opinion of SCANIS' counsel in a form reasonably satisfactory
                    to   ICAD   with   respect   to   the   due   authorization,
                    enforceability,  binding  effect and validity in  accordance
                    with its terms of this Exclusive License Agreement.

          b.   In the event that the  conditions  set forth at section  5(a) are
               not  satisfied  as  aforesaid,  ICAD may  cancel  this  Exclusive
               License Agreement without further obligation by written notice to
               SCANIS,  and  SCANIS  shall be  obligated  to repay  the  initial
               License Fee as set forth at section 4(a), within thirty (30) days
               after such  written  notice.  At the written  election of SCANIS,
               such  License  Fee  payment  obligation  may  be  converted  to a
               12-month  term  loan  at  an  interest  rate  of  5%  per  annum,
               compounded monthly and payable in equal monthly installments.

     6.   TERM.  The term of this  Agreement,  the licenses,  and  Non-Assertion
          Agreement  granted herein shall exist from and including the Effective
          Date to and including the expiration  date of the Licensed  Patent and
          until all claims for alleged  infringement  of all the Licensed Patent
          and Licensed Patent Rights are barred by U.S. laws and the U.S. patent
          statute.

     7.   PATENT ENFORCEMENT.

          a.   If SCANIS becomes aware that any third party is infringing or may
               be infringing upon the Licensed Patent or Licensed Patent Rights,
               SCANIS  agrees that it will provide  ICAD with written  notice of
               such  infringement.  SCANIS agrees that it will provide ICAD with
               such a notice of  infringement  promptly,  but in any event by no
               later  than  ten  (10)  days  after  it  becomes  aware  of  such
               infringement.

          b.   ICAD  shall have the sole  right at its  expense  to enforce  and
               defend the Licensed  Patent and Licensed Patent Rights within the
               United States related to past, present,  or future  infringement.
               In this regard, ICAD shall have the sole right to take any action
               in  response  to  actual or  possible  past,  present,  or future
               infringement  of the Licensed  Patent or Licensed  Patent Rights,
               including  but not  limited  to the  right to  make,  in its sole
               discretion,  all  decisions  as to: (i)  whether to  commence  an
               action, suit, or proceeding against any infringer of these rights
               and/or defend against an action, suit, or proceeding brought by a
               third  party;  (ii) the manner in which it conducts  this action,
               suit, or proceeding;  (iii) whether to resolve such action, suit,
               or proceeding through settlement;  and (iv) the terms under which
               it may settle such action, suit, or proceeding. ICAD reserves the
               right,  in its sole  discretion,  to resolve  any  threatened  or
               pending legal action  pertaining  to the Licensed

<PAGE>

               Patent and the  Licensed  Patent  Rights by granting a license to
               such third party on terms ICAD deems to be acceptable.

          c.   SCANIS  shall  cooperate  with  ICAD  in  any  action,  suit,  or
               proceeding,  including permitting ICAD to prosecute and/or defend
               in SCANIS' name, add SCANIS as an  indispensable  party,  provide
               ICAD with access and copies of any relevant documents, witnesses,
               or other  materials  that are  reasonably  required to  prosecute
               and/or defend ("Cooperate").

     8.   RELATIONSHIP OF THE PARTIES.

          a.   Nothing  contained in this Agreement  shall be deemed to (i) make
               either party or any  employee of such party the agent,  employee,
               joint venture or partner of the other party;  (ii) provide either
               party or any  employee of such party with the power or  authority
               to act on behalf of the other party or to bind the other party to
               any contract, agreement or arrangement with any other person.

          b.   All personnel employed or otherwise engaged by either party shall
               be the agents,  servants,  and employees of such party only,  and
               the  other  party  shall  incur no  obligations  or  liabilities,
               express or implied, by reason of the conduct of such personnel.

     9.   WAIVER.  Waiver by either party hereto of any breach or default by the
          other party of any of the terms and conditions of this Agreement shall
          not  operate  as a waiver of any  other  breach  or  default,  whether
          similar to or different from the breach or default waived. A party may
          only be deemed to have waived any breach or default by the other party
          if that waiver is in writing and is signed by that party.

     10.  COSTS AND EXPENSES.  Except as otherwise  provided in this  Agreement,
          each party hereto shall be responsible  for its own expenses  incurred
          in  connection  with the  performance  of its  obligations  under this
          Agreement.

     11.  ENTIRE  AGREEMENT.   This  Agreement  and  the  Non-Exclusive  License
          represents the entire  understanding and agreement between the parties
          hereto  with  respect  to the  subject  matter of this  Agreement  and
          supersedes all prior or contemporaneous negotiations, representations,
          and agreements made by and between the parties concerning that subject
          matter.  No alteration,  amendment or modification of any of the terms
          or provisions of this Agreement shall be valid unless made pursuant to
          an  instrument  in  writing  signed  by  each of the  parties  hereto;
          provided,   however,  that  the  waiver  by  either  party  hereto  of
          compliance  by the other  party  with any  provision  hereof or of any
          breach or default of such other party need be signed only by the party
          waiving such provision,  breach or default. In the event of a conflict
          between the Non-Exclusive  License and this Agreement,  this Agreement
          shall control,  provided that consideration and royalties provided for
          from ICAD to SCANIS in the  Exclusive  License  Agreement  shall be in
          addition to consideration of any kind provided for from ICAD to SCANIS
          in the Non-Exclusive Agreement.

     12.  GOVERNING LAW. This Agreement  shall be governed by and interpreted in
          accordance  with the laws of the  State of New  York,  excluding  that
          state's conflict of laws principles.

     13.  NON-ASSIGNMENT.  Except as expressly  provided  herein,  or at section
          3(d), SCANIS may not assign,  transfer,  encumber,  or sub-license its
          rights under this Agreement to any other person or entity,  whether by
          operation of law or otherwise,  without the prior  written  consent of
          ICAD, which may be withheld in ICAD's sole discretion.  Any assignment
          or purported assignment by SCANIS in violation of this paragraph shall
          be null and void.  ICAD may freely  share,  assign,  or  transfer  its
          interests or this Agreement.

     14.  NOTICES.  All  notices  provided  for in this  Agreement  shall  be in
          writing  and  effective  when  they  are  served  either  by  personal
          delivery,  or  sent  by  letter  by  overnight  courier  service  with
          acknowledgment  of  receipt  required  and   simultaneously   sent  by
          facsimile  to the  receiving  party as of the date of the  signing  or
          first refusal to sign the return receipt,  to the following  people at
          the following address:

                         If to ICAD:

                         Chief Executive Officer
                         iCAD, Inc.
                         4 Townsend West, Suite 17, Nashua, NH 03063
                         Fax: (603) 880-3843

<PAGE>

                         With a required copy to:
                         Robert Mittman
                         Blank Rome LLP
                         The Chrysler Building
                         405 Lexington Avenue
                         New York, NY 10174

                         If to SCANIS:
                         Chief Executive Officer
                         SCANIS, INC.
                         1111 Triton Drive, Suite 201, Foster City, CA 94494
                         Fax: (650) 378-4109

          or such other addresses  either party shall  hereinafter  designate in
          writing to the other party.

     15.  INVALIDITY  OF  PROVISIONS.  If a court  or  other  body of  competent
          jurisdiction  determines  that  any  provision  of this  Agreement  is
          unenforceable,  it is  agreed  that  such  unenforceability  shall not
          invalidate the whole agreement,  but this Agreement shall be construed
          as to that situation as if it did not contain such  provisions and the
          rights and  obligations  of the parties  hereto shall be construed and
          enforced   accordingly,   but  such  provisions  and  the  rights  and
          obligations  of the parties  hereto  shall not be affected as to other
          situations where the provision is not unenforceable.

     16.  BANKRUPTCY.  The  parties  understand  that all  rights  and  licenses
          granted  hereunder  are  licenses to rights to  intellectual  property
          under Section 365(n) of the Bankruptcy Act and,  therefore,  if SCANIS
          becomes subject to bankruptcy  proceedings,  ICAD shall retain and may
          fully exercise all of their rights and elections  under the Bankruptcy
          Code as licensees of that intellectual property.

     17.  RIGHT OF FIRST  REFUSAL/OPTION  TO PURCHASE  LICENSED  PATENT.  In the
          event that SCANIS proposes to sell,  transfer,  or assign the Licensed
          Patent or the Licensed Patent Rights,  it shall give written notice of
          the potential sale,  transfer,  or assignment to ICAD. ICAD shall have
          thirty (30) days from receipt to give written notice to SCANIS that it
          will purchase the Licensed Patent or the Licensed Patent Rights on the
          same price terms as the proposed sale,  transfer,  or  assignment.  If
          ICAD  declines  the  offer by  written  notice  to  SCANIS or fails to
          respond  within  thirty (30) days,  SCANIS may  complete  its proposed
          transaction with that proposed buyer or assignee on substantially  the
          same terms as contained  in the notice to ICAD of the  proposed  sale,
          transfer,  or  assignment.  In the  event  that  SCANIS  ceases  to do
          business,  if a petition in bankruptcy has been filed by or against it
          (if it is an involuntary petition, it is not dismissed within 60 days)
          or it has  made an  assignment  for the  benefit  of  creditors,  or a
          receiver  has been  appointed  for the other party or any  substantial
          portion of other party's property,  then ICAD shall have an option, in
          its sole discretion, for 60 days after written notice of such event to
          purchase the Licensed  Patent and the Licensed  Patent  Rights for the
          fair  market  value of the  Licensed  Patent and the  Licensed  Patent
          Rights at that time, based on a fair appraised value.

     18.  ATTORNEYS'  FEES.  If any action is  commenced  to enforce or construe
          this Agreement,  the Party who  substantially  prevails in that action
          shall be entitled to recover all costs and expenses  that Party incurs
          in the  prosecution  or  defense  of that  action,  including  but not
          limited to reasonable attorneys' fees, in addition to any other relief
          to which that Party is entitled.

     19.  LATE  PAYMENTS.  Amounts owing under this  Agreement that are not made
          when due shall  accrue  interest at a rate of one  percent  (1.0%) per
          month or the maximum amount of interest  allowed under  applicable law
          (whichever is less) until such amounts are paid in full.

     20.  TITLES.  All  titles  used  in  this  Agreement  herein  are  for  the
          convenience of reference only and shall not affect the construction of
          this Agreement.

     21.  DUPLICATE  ORIGINALS.  This  Agreement  shall be executed in duplicate
          originals and may first be delivered by  facsimile.  Execution of this
          Agreement  by the parties and delivery  thereof by facsimile  shall be
          valid and binding as of the Effective Date,  which will be inserted in
          the preamble. This Agreement may be executed separately by each of the
          parties and exchanged by facsimile to establish  the  Effective  Date.
          Within  thirty (30) days of  facsimile  execution,  the parties  shall
          deliver and exchange fully executed originals of the Agreement.

<PAGE>

     22.  INDEPENDENT RIGHT OF ENFORCEMENT.  In the event that Scanis identifies
          what it  deems  to be an  infringement  of the  Licensed  Patent,  and
          provides iCAD with written notice thereof, iCAD shall inform Scanis in
          writing as to whether iCAD will seek to enforce such  Licensed  Patent
          with  respect to such  alleged  infringer,  whether by  litigation  or
          negotiation  or  otherwise.  In the event that iCAD so informs  Scanis
          that  iCAD  will not seek to so  enforce  such  Licensed  Patent  with
          respect  to such  alleged  Infringer,  Scanis  shall  have all  rights
          permitted by applicable  law to seek,  at its own expense,  to enforce
          such  Licensed  Patent  against such alleged  Infringer.  In the event
          Scanis so enforces  the Licensed  Patent and secures any  damages,  or
          royalties  with respect  thereto,  Scanis shall retain such damages or
          royalties.

         ++

IN WITNESS  WHEREOF,  the  parties  hereto  have  caused  this  Agreement  to be
executed, in duplicate, by their duly authorized officers or representatives.

SCANIS, INC.

By:   /s/  Robert L. Chapman
  -------------------------------------------------------
  Robert L. Chapman, Chairman and Chief Executive Officer

Witness:  /s/ Margaret Ferris
       --------------------------------------------------

iCAD, Inc.

By:  /s/ W. Scott Parr
  -------------------------------------------------------
      W. Scott Parr, President & CEO

Witness:  /s/ Meredith A. A. Parr
       --------------------------------------------------

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00055-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00055-of-00352.parquet"}]]